AllDocs -> cancers

J ULY 1999 • V OL . 6 192 • more frequently) and it is less common when the woman is on the contraceptive pill,which has a protective effect. The “average patient” presents with non- specific abdominal symptoms, such as distension and bloating.Three-quarters will have advanced disease,beyond the pelvis. Approximately 90 per cent of ovarian cancers are epithelial in origin.They may be divided into benign, borderline or malig- nant. The malignant epithelial tumours are the major cause of death and morbidity, and Special Feature By H. T HOMAS , FRCP, FRCR This month ovarian cancer is the topic of our special feature.This first article gives an overview of the possible causes,pathology and management of the disease.The second article details the treatment strategies which are available ...

stage at presentation. Staging is carried out surgically as ovarian cancers are found deep in the peritoneal cavity and staging cannot be carried out using currently available scanning techniques.There are a number of different types of ovarian cancers, of which epithelial tumours account for 90 per cent, and the different tumour types all require slightly different management. For this rea- son, this article will be limited to discussing the treatment of epithelial ovarian cancers. Sex cord/stromal tumours and germ cell tumours constitute the majority of non- epithelial cancers. It is impossible to discuss treatment of ovarian cancer without first defining the dif- ferent stages.The currently accepted staging from the International Federation of Gynae- cology and Obstetrics (FIGO) is shown in Table 1. O VERVIEW OF SURGERY A lthough ...

Yu et al. / J Zhejiang Univ SCI 2005 6B(4):227-231 227 An integrated approach utilizing proteomics and bioinformatics to detect ovarian cancer * YU Jie-kai (?) 1,2 , ZHENG Shu (? ?) †1 , TANG Yong (? ?) 3 , LI Li (? ?) 3 ( 1 Cancer Institute, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, China ) ( 2 School of Life Science, Zhejiang University, Hangzhou 310029, China ) ( 3 Affiliated Tumor Hospital of Guangxi Medical University, Nanning 530021, China ) † E-mail: zhengshu@mail.hz.zj.cn Received Aug. 20, 2004; revision accepted Oct. 15, 2004 Abstract: Objective: To find new potential biomarkers and establish the patterns for the detection of ovarian cancer . Methods: Sixty one serum samples including ...

Abstract. YKL-40 (human cartilage glycoprotein-39) is a member of family 18 glycosyl hydrolases. YKL-40 is a growth factor and is secreted by cancer cells. High serum levels of YKL-40 in patients with colorectal cancer and recurrent metastatic breast cancer have been associated with a poor prognosis. We evaluated the prognostic value of plasma YKL-40 in patients with primary ovarian cancer (OC). YKL-40 was determined by ELISA in plasma obtained preoperatively from 47 women with stage III OC and in plasma from 79 healthy females. The results showed that plasma YKL-40 was elevated compared to healthy females in 57% of the OC patients and was highest in the patients who died during the follow-up compared to the patients still alive (186 vs. 78 µ g/l, p=0.002). Patients with high plasma YKL-40 (>130 µ g/l) had significantly (p=0.0003) shorter survival than patients with normal plasma YKL-40. ...

Ovarian Cancer Page 2 WellBeing of Women Funding Vital Health Research WellBeing of Women is about life – helping enable it, sustain it and make it the best quality. Women are the motivating factor for us and our aim is for women everywhere to be free of fear and suffering from reproductive problems. Our determination to meet the health needs of women today is as strong as it was in 1964 when the charity started. WellBeing of Women is dedicated to the challenge of raising greater awareness and securing more support and funds to invest in new medical research in three key areas of reproductive health: G Gynaecological Cancers G Pregnancy and Birth G Quality of Life problems If you would like to know more about WellBeing of Women , please contact us at: WellBeing of Women 27 Sussex Place ...

Dr Eric Pujade-Lauraine is currently the Head of the French GINECO Group devoted to clinical research in gynaecologic cancer . He is also the Head of the Medical Oncology Unit in the Department of Haematology-Medical Oncology at Hôpital Hôtel-Dieu in Paris, France. While receiving his medical degree from the University of Paris VI, he was an intern at Assistance Publique des Hôpitaux de Paris. He later earned his PhD from the University of Paris VI, where he is now a Professor of Medical Oncology. As well as serving on several advisory boards, Dr Pujade- Lauraine is also a member of the American Society of Clinical Oncology, the European Society for Medical Oncology, and the Gynecologic Cancer Intergroup. B U S I N E S S B R I E F I N G : E U R O P E A N P H A R M A C O T H E R A P Y 2 0 0 5 85 Ovarian Cancer a report by ...

J Pharm Pharmaceut Sci (www.cspscanada.org) 7(4):29-34, 2004 29 Corresponding Authors: Steve McQuarrie, Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada. steve.mcquarrie@ualberta.ca Preliminary results of nanopharmaceuticals used in the radioimmunotherapy of ovarian cancer . Steve A McQuarrie, John R Mercer, Alasdair Syme, Mavanar R Suresh and Gerald G Miller Faculty of Pharmacy and Pharmaceutical Sciences; Noujaim Institute for Pharmaceutical Oncology Research, University of Alberta, Edmonton, Alberta, Canada Received 16 July 2004, Revised 17 December 2004, Accepted 19 January 2005, Published 10 February 2005 ABSTRACT Purpose : The treatment of late stage ovarian cancer presents an unmet clinical need for women around the world. A multistep radioimmuno- therapeutic (RIT) approach, exploiting the combina- tion ...

1 1 ACTA FACULTATIS PHARMACEUTICAE UNIVERSITATIS COMENIANAE Tomus LI 2004 QUALITY OF LIFE IN CHEMOTHERAPY OF OVARIAN CANCER Lišcáková, A. – Majtás, J. Department of Organization and Management in Pharmacy, Faculty of Pharmacy, Comenius University, Bratislava Owing to the modern chemotherapy lives can be often saved. The quality of life of the patients can serious be impaired and its exterior appearance be visibly changed by the side effects of a chemotherapy. Straight ones in the last years became however with the therapy accom- panying treatment of the side effects, which so-called supportive therapy obtains, substantial progress. Therefore it is very important to argue also with the side effects and their treatment comprehensively. For the treatment of cancer illnesses nowadays highly effective medicines stand for order apart from operation and radiotherapy ...

Composite • Your risk increases if you have had breast cancer , or if you have a family history of breast, colorectal or ovarian cancer . How can I detect ovarian cancer early? • If you are 18-40 have a pelvic exam (recto- vaginal) by your doctor every 1-3 years. • If you are over 40 have a yearly check up with pelvic exam (recto-vaginal). • Pap tests are useful in finding cervical cancer , but they rarely find early ovarian cancer . • Talk to a doctor if you have any symptoms or signs that suggest ovarian cancer . You may want to request that your doctor order tests. These tests are not recommended for routine screening. The tests may include: Ultrasound (transvaginal). A special blood test called CA 125 that checks for ovarian cancer tumors. How do you treat ovarian cancer ? • ...

HEREDITARY BREAST and OVARIAN CANCER Background information Cancer is a common disease. All of us start with about a 1 in 3 (30%) chance of developing cancer (excluding skin cancer ) over the course of our lives. In this country, women have a 1 in 8 (12%) chance of developing breast cancer and a 1 in 70 (1%-2%) chance of developing ovarian cancer over the course of their lifetime. Cancer can cluster in a family for several reasons including shared environmental exposures, similar lifestyles, and chance events. Only about 5%-10% of all cases of ovarian or breast cancer are strongly inherited. In these cases, there tends to be a specific pattern of cancer in the family: diagnoses at unusually early ages, several relatives affected with the same or related type of cancer , and individuals with more than one primary tumor. An inherited factor, ...

VI. Ovarian Cancer Research Program Page 2 Ovarian Cancer Research Program VI-2 Vision: To eliminate ovarian cancer . Mission: To support innovative, integrated, multidisciplinary research efforts that will lead to better understanding, detection, diagnosis, prevention, and control of ovarian cancer . Congressional Appropriations for Peer Reviewed Research: ¦ $61.7M in FY97–02 ¦ $10M in FY03 ¦ $10M in FY04 Funding Summary: ¦ 63 awards from the FY97–02 appropriations ¦ 17 awards from the FY03 appropriation ¦ 1ds anticipated from the FY04 appropriation The Disease Ovarian cancer ranks second among gynecological cancers in the number of new cases and first among gynecological ...

Promotional/Educational Materials Order Form “Maintain Your Gynecologic Health with Education Please send me __ copies each & Early Detection” Brochure (English/Spanish) Circle one. Ovarian Cancer National Resource List Brochure Please send me __ copies each (English/Spanish) Circle one. “Beating The Odds” Brochure Please send me __ copies each Ad Slick Promoting 1/800-444-4441 Information Hotline (8.5” x 11”) Please send me __ copies each Ad Slick Featuring The Talk Show Hosts of The View (8.5” x 11”) Please send me __ copies each Poster Featuring The Talk Show Hosts of The View (16 x 14) Please send me __ copies each Ad Slick Featuring Miss USA/Miss USA Tent Card Please send me __ copies each Cervical Cancer Awareness Month Tent Card Please send me __ copies each Women’s Cancer Network Web ...

HUMAN GENE THERAPY 13:1505–1514 (August 10, 2002) © Mary Ann Liebert, Inc. Brief Report Serum and Ascites Neutralizing Antibodies in Ovarian Cancer Patients Treated with Intraperitoneal Adenoviral Gene Therapy AKSELI HEMMINKI, 1,2 MINGHUI WANG, 1 RENEE A. DESMOND, 3 THERESA V. STRONG, 4 RONALD D. ALVAREZ, 5 and DAVID T. CURIEL 1 1505 OVERVIEW SUMMARY Neutralizing antibodies (NAbs) can inhibit gene transfer by adenovirus in preclinical models, but this has not been con- firmed in human trials, which have mostly utilized local de- livery. Heretofore, it has not been studied whether in- traperitoneal administration of adenovirus to ovarian cancer patients results in induction of NAbs in ascites or serum. Also, it is not known how ascites and serum NAbs correlate, ...

Replication of an integrin targeted conditionally replicating adenovirus on primary ovarian cancer spheroids John T Lam, 1 Gerd J Bauerschmitz, 1 Anna Kanerva, 1 Shannon D Barker, 1 J Michael Straughn, 2 Minghui Wang, 1 Mack N Barnes, 2 Jerry L Blackwell, 1 Gene P Siegal, 3 Ronald D Alvarez, 2 David T Curiel, 1 and Akseli Hemminki 1,4 1 Division of Human Gene Therapy, Departments of Medicine, Pathology and Surgery, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA; 2 Division of Gynecology Oncology, Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA; 3 Departments of Pathology, Cell Biology, and ...

The research challenge The early diagnosis of many forms of cancer remains one of medicine's greatest challenges. It is now widely known that, for many cancers, if the disease is detected early, treatment is much more successful. In ovarian cancer in particular, approximately 70% of cases are not detected until an advanced stage, leading to a 5 year survival rate of only 25%. However if the cancer is detected at an early stage, five year survival rate increases to 90%. There were over 1200 new cases of ovarian cancer diagnosed in Australia in 1998, and over 750 women died. Currently, there are two tests used to detect ovarian cancer – measuring levels of a protein marker in blood plasma (CA125), which is thought to be increased in ovarian cancer and transvaginal ultrasonography, an ultrasound of the ovaries. Unfortunately, these ...

The research challenge Ovarian cancer is the fourth commonest cause of cancer deaths in Australian women. The cancer is often silent until it is quite advanced, so that treatment is not as effective as in other cancers such as breast and cervical cancer which are usually detected earlier. The overall 5-year survival is less than 30%. There is a 60-70% chance of disease recurrence within two years of standard treatment with surgery plus chemotherapy. The path to discovery We are testing a new type of therapy for ovarian cancer . The therapy involves stimulating the patient's immune system to fight the cancer . The therapy is administered in addition to the first-line treatment currently available, namely excision of the tumour followed by 6 courses of chemotherapy at monthly intervals. The therapy is being offered to women enrolled ...

Ovarian Cancer The National Cancer Institute ( http://www. cancer .gov/ ), lists ovarian cancer as one of 13 common causes of cancer and provides the following information. To obtain a free copy of this document, go to www.masterdocs.com . Understanding Cancer Cancer begins in cells, the building blocks that make up tissues . Tissues make up the organs of the body. Normally, cells grow and divide to form new cells as the body needs them. When cells grow old, they die, and new cells take their place. Sometimes this orderly process goes wrong. New cells form when the body does not need them, and old cells do not die when they should. These extra cells can form a mass of tissue called a growth or tumor . Not all tumors are cancer . Tumors can be benign or malignant : Benign tumors are not cancer : • Benign tumors are rarely life-threatening. ...

Reference Section a report by Er nest Han , MD , PhD , and Rober t A Burger , MD First Year Fellow in Gynecologic Oncology and Associate Professor of Clinical Obstetrics and Gynecology, Division of Gynecologic Oncology, University of California, Irvine Epidemiology Ovarian cancer represents 6% of all female cancer diagnoses, and is the fifth leading cause of cancer mortality in women in the US. 1 Similarly,in the UK,5% of all cancers in women originate from the ovary, and ovarian cancer is the fourth leading cause of cancer death. 2 In 2004,it is estimated that 25,580 new cases and 16,090 deaths will result from ovarian cancer in the US. 1 Ovarian cancer can be classified as either epithelial or non-epithelial. This review ...

Pharmacologic Therapies OVARIAN CANCER 24 B U S I N E S S B R I E F I N G : U S O N C O L O G Y R E V I E W 2 0 0 4 a report by Alan N Gordon , MD Clinical Professor of Obstetrical Gynecology, University of Arizona School of Medicine Ovarian cancer remains the leading cause of death from gynecologic malignancies.Although endometrial cancer occurs more frequently, the vast majority of patients who develop this disease present with post- menopausal or other irregular bleeding problems and are usually diagnosed with early-stage disease and experience long survival. In contrast, the presenting signs and symptoms of ovarian cancer are non- specific, and almost 75% of patients already have extensive abdominal disease at the time of diagnosis (stage IIIC and IV). The failure to be able to detect ovarian cancer at earlier ...

GO Fund Research Report 2004 24 December 2004 Page 1 Ovarian Cancer – Research Holds the Answers The GO Fund’s 2004 Research Report The biggest problem with diagnosing ovarian cancer – the 5 th highest cancer killer in women – is the lack of early warning signs. Therefore, 75% of women present with advanced stage disease. Despite some improvement in 5-year survival rates over the past 20 years, the outlook is still poor, the overall survival being only 40%. This figure will be dramatically improved if we can find a way to pick up early stage disease, which is therefore the major goal of our research. Research Goals • To find a blood test for the early detection of ovarian cancer , to allow population-based screening; • To find molecular treatment options for women with advanced disease; • To identify ways to predict patients ...

Ovarian Cancer a report by Er nest Han , MD , PhD and Rober t A Burger , MD First Year Fellow in Gynecologic Oncology and Associate Professor of Clinical Obstetrics and Gynecology, Division of Gynecologic Oncology, University of California, Irvine Epidemiology Ovarian cancer represents 6% of all female cancer diagnoses, and is the fifth leading cause of cancer mortality in women in the US. Similarly, in the UK, 5% of all cancers in women originate from the ovary, and ovarian cancer is the fourth leading cause of cancer death. In 2004, it is estimated that 25,580 new cases and 16,090 deaths will result from ovarian cancer in the US. Ovarian cancer can be classified as either epithelial or non-epithelial. This review will focus on epithelial ovarian cancers, ...

Prospective multicenter ovarian cancer screening trial of women at high risk: Preliminary results from the first 2,200 women. Steven J. Skates , Nora K. Horick , Dianne M. Finkelstein , Karen H. Lu for the ROCA study group . Massachusetts General Hospital, Boston, MA; UT MD Anderson Cancer Center, Houston, TX. Objectives. Women with a BRCA mutation have a 20 to 40 percent lifetime risk of ovarian cancer . 1 The current recommendation for such women for reducing the risk of ovarian cancer is prophylactic oophorectomy. 2 Nonetheless, some high-risk women choose to retain their ovaries, even though no proven screening strategies exist for this high-risk group. 3 4 Other women at elevated risk include subjects from families with multiple ovarian or breast cancers. A multicenter prospective ovarian cancer screening study of women at high risk ...

The BOADICEA model of genetic susceptibility to breast and ovarian cancer : updating, validation and predictions. Antonis C. Antoniou (1), Paul D.P Pharoah (2) and Douglas F Easton (1) on behalf of the Boadicea collaborators. (1) CR-UK Genetic Epidemiology Unit, (2) Human Cancer Genetics Group, University of Cambridge, UK Several genes conferring susceptibility to breast and ovarian cancer , notably BRCA1 and BRCA2, have been identified. The majority of the familial aggregation to breast cancer is, however, not explained by these genes. We have previously derived a susceptibility model using segregation analysis of breast and ovarian cancer occurrence in a combined dataset, including a population-based series of 1,484 breast cancer cases and 156 high- risk families from the UK (Antoniou et al., Br J Cancer , 2002). We are currently updating this model using additional data from two UK population-based ...

2004 • 2005 Directory of Genetics Support Groups, Services and Information 307 Produced by the Centre for Genetics Education. Fax: (02) 9906 7529 Email: genetics@med.usyd.edu.au Internet: http://www.genetics.com.au BREAST AND OVARIAN CANCER – GENETIC ASPECTS 45 BREAST AND OVARIAN CANCER • Breast cancer is the commonest form of cancer occurring in women in Australia. It affects about 1 in 12 women in their lifetime. • Cancer of the ovaries affects only about 1 in 100 women before the age of 75. However, it is the leading cause of death from gynaecological cancer . Breast cancer also occurs in men, but it is rare. CAUSES OF BREAST/ OVARIAN CANCER The causes of breast and ovarian cancer are complex and involve interactions between genetic and environmental factors. (a) Genetic factors Cancer is a disease of the body’s cells. ...

Advice about familial aspects of breast cancer and ovarian cancer - A guide for health professionals These guidelines contain three parts: 1 . Information for health professionals 2.Tables which describe three categories of women according to their family history of breast or ovarian cancer , their risk of cancer , and the current suggested management for each category 3.Information for consumers The guidelines have been developed to cover familial aspects of both breast and ovarian cancer . This is because two genes, BRCA1 and BRCA2 have recently been discovered. Women who have been born with a mutation in either of these genes are at a high risk of both breast cancer and ovarian cancer . The families in which these women are most likely to be found are those with multiple cases of breast and/or ovarian cancers, in different generations on the same side of the family. The information on page ...

Ovarian Cancer – Facts and Myths Ovarian Cancer – Facts and Myths Gary S. Leiserowitz, M.D. Gary S. Leiserowitz, M.D. Associate Professor and Associate Professor and Chief Chief Division of Gynecologic Division of Gynecologic Oncology, UCDMC Oncology, UCDMC Page 2 Ovarian Cancer Ovarian Cancer What is ovarian cancer ? What is ovarian cancer ? Ovarian cancer arises from cells within Ovarian cancer arises from cells within the ovary the ovary Ovarian cancer is the leading cause of Ovarian cancer is the leading cause of death among female genital cancers death among female genital cancers 25,000 new cases /year of ovarian 25,000 new cases ...

Familial Breast and Ovarian Cancer Genetics, Screening and Management Edited by Patrick J. Morrison Belfast City Hospital Trust, Belfast, UK Shirley V. Hodgson Guy’s Hospital, London, UK and Neva E. Haites University of Aberdeen, Aberdeen, UK www.cambridge.org © Cambridge University Press Cambridge University Press 052180373X - Familial Breast and Ovarian Cancer : Genetics, Screening and Management Edited by Patrick J. Morrison, Shirley V. Hodgson and Neva E. Haites Copyright Information More information Page 2 published by the press syndicate of the university of cambridge The Pitt Building, Trumpington Street, Cambridge, United Kingdom cambridge university press The Edinburgh Building, Cambridge CB2 2RU, UK 40 West 20th Street, New York, NY 10011-4211, USA ...

Familial Breast and Ovarian Cancer Genetics, Screening and Management This book surveys the profound and far-reaching ramiWcations that have arisen from the very signiWcant advances in our understanding of the genetic basis of familial breast and ovarian cancer . Written by international experts from Europe and North America, it provides the busy clinician with a contemporary and wide-ranging guide to the latest developments in the diagnosis, genetics, screening, prevention and management of familial breast cancer . In this rapidly advancing Weld, this book provides an unrivalled source of information, including sections on ethical and insurance issues and the diVerent cultural aspects of breast cancer . The use of recently devised cancer genetics clinics and diVerent referral criteria and patterns to these clinics are also detailed. This accessible book will be of immense value to all clinical geneticists, ...

Ovarian Cancer The chances of getting ovarian cancer According to the American Cancer Society: • the risk of getting ovarian cancer increases as a woman gets older • ovarian cancer accounts for 4 percent of all cancers in women • ovarian cancer is the fifth in cancer deaths among women Are you at risk? You may be at increased risk for developing ovarian cancer if you: • started your periods before you were 12 • started menopause after the age of 50 • never had children or had your first child after the age of 30 Symptoms Early ovarian cancer may have no specific symptoms. See your doctor if you experience: • abdominal swelling or discomfort (gas, bloating, cramps) that doesn’t go away ...

[Frontiers in Bioscience, 1 g56-59, January 1, 1996] 56 OVARIAN CANCER : NATURAL HISTORY AND METASTATIC PATTERN Amadori D., MD, Sansoni E.,MD, Amadori A., MD Department of Medical Oncology- Pierantoni Hospital, Via Forlanini, 34 47100 FORLI’, Italy TABLE OF CONTENTS 1. Abstract 2. Discussion 3. Conclusions 4. References 1. ABSTRACT Ovarian cancer begins at a molecular level, however to date, our knowledge of genetic changes and mechanisms of ovarian tumorigenesis is limited. The natural history of ovarian cancer may depend on different anatomo-clinical and biological factors. In the life history of ovarian cancers the stage, histology, tumor grade, age of the patient and gene abnormalities, both oncogenes (c-myc, H-ra, new) and oncosuppressor genes (p53, in particular), DNA ploidy and steroid receptor status have important ...